Clinical outcome of certolizumab pegol use in patients with rheumatoid arthritis

Kondo Naoki, Kudo Naoko, Fujisawa Junichi, Endo Naoto

doi:10.14961/cra.31.314

Aim: To examine the clinical outcome of certolizumab pegol（CZP）in patients with rheumatoid arthritis（RA）.Methods: Eighteen patients with RA（16 women and 2 men; mean age, 58.5±12.1 years; age range, 25-75 years; average disease duration, 6.3 years）who were given CZP were registered; of these 18 patients, 7 were biological agent–naïve. Twenty-one biological agents were previously used（etanercept, 8; adalimumab, 4; tocilizumab, 4; abatacept, 2; infliximab, 2; golimumab, 1）. Methotrexate was used in 14 cases（average dose, 7.1 mg/week; range, 4-10 mg/week）. Prednisolone was used in 5 cases（average dose, 4.5 mg/day; range, 2.5-5 mg/day）. The Disease Activity Score 28（DAS28）, European League Against Rheumatism response, retention rate, and adverse events were examined.Results: The DAS28 score significantly decreased from 4.34（at first CZP administration）to 3.73（at 1.5 months after CZP administration）（p=0.0008）, to 3.10（at 3 months）（p=0.0037）, to 2.53（at 6 months）（p = 0.0006）, and 2.67（at 12 months）（p = 0.0019）. Moderate response was acquired in most cases（13/18, 72.2%）. The continuation rate was 67% at 24 weeks and 61% at 1 year. Administration was suspended for being ineffective in 5 cases（all of which were primary failures）and due to adverse events in 2 cases（1 for pain during injections and 1 because of worsening bronchial asthma, which was an underlying disease）.Conclusions: Despite the high rate of refractory RA cases in this study, DAS28 showed low disease activity 6 months after CZP treatment, suggesting that CZP is effective for patients with refractory RA.

Clinical outcome of certolizumab pegol use in patients with rheumatoid arthritis

Bibliographic Information

Description

Journal

Keywords

Details 詳細情報について

Export

Report a problem